Min Yuen Teo

Abstract With the approval of the antibody-drug conjugate enfortumab vedotin (EV), NECTIN4 has emerged as a bona fide therapeutic target in urothelial carcinoma (UC). Here, we report the development of a NECTIN4-directed chimeric antigen receptor (CAR) T cell, which exhibits reactivity across cells expressing a range of endogenous NECTIN4, with enhanced activity in high expressors.

Correction to: Nature Communications https://doi.org/10.1038/s41467-022-34251-3, published online 02 November 2022 In this article the author name Ziyu Chen was incorrectly written as Zhiyu Chen. The original article has been corrected. Author information Author notes These authors contributed equally: Joshua I. Warrick, Wenhuo Hu, Hironobu Yamashita.

Abstract Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of urothelial carcinoma adjacent to or admixed with regions of divergent histomorphology, most commonly squamous differentiation. To define the biologic basis for and clinical significance of this morphologic heterogeneity, here we perform integrated genomic analyses of mixed histology bladder cancers with separable regions of urothelial and squamous differentiation.